Inhibikase Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview

Inhibikase Therapeutics

10/05/2024 16:14

* Inhibikase Therapeutics Inc  IKT.OQ   IKT.O  is expected
to show
no change in quarterly revenue when it reports  results on May
13 (estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Inhibikase Therapeutics
Inc is
for a loss of 79 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 9.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $17.50​, above​ its last closing price
of $1.36. ​​​

This summary was machine generated May 10 at 15:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)